Ultra Metabolism
Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen’s investigational drug for the treatment of obesity, in the United States, Canada and Mexico.
UltraMetabolism Live Presentation
Metabolism Masterclass